Home > Insider Trading > Filing (0001209191-23-007907)

Filing Details

Accession Number:: 0001209191-23-007907
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-02-08 19:18:52
Reporting Period:: 2023-02-06

Accepted Time:: 2023-02-08 19:18:52
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
914475	Neurocrine Biosciences Inc	NBIX	Biological Products, (No Disgnostic Substances) (2836)	330525145

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1643653	Eric Benevich	12780 El Camino Real San Diego CA 92130	Chief Commercial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2023-02-06	1,280	$105.63	17,879	No	4	S	Direct
Common Stock	Disposition	2023-02-07	2,030	$102.29	19,705	No	4	S	Direct
Common Stock	Disposition	2023-02-07	15,360	$102.42	33,501	No	4	S	Direct
Common Stock	Disposition	2023-02-08	980	$104.12	34,381	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

Sale of 1,280 shares of common stock issued upon vesting of 2,430 restricted stock units on February 6, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,150) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.60 to $107.30. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Sale of 2,030 shares of common stock issued upon vesting of 3,856 restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,826) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.74 to $103.87. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Sale of 15,360 shares of common stock issued upon vesting of 29,156 performance restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (13,796) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on February 7, 2023.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.02 to $103.96. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Sale of 980 shares of common stock issued upon vesting of 1,860 restricted stock units on February 8, 2023 to cover payroll and withholding taxes, with the balance of the shares (880) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.58 to $106.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.